Special Issue "Marine Anti-inflammatory Agents"
A special issue of Marine Drugs (ISSN 1660-3397).
Deadline for manuscript submissions: 30 June 2018
Acute inflammation is a highly-regulated process, and its dysregulation can lead to the development of a chronic inflammatory state, which is believed to play a main role in the pathogenesis of many diseases, including cancer. The molecular mechanisms underlying chronic inflammation are beginning to be elucidated: Reactive oxygen species (ROS) stimulate intracellular signaling pathways and transcription factors, including MAPK and NF-kB. ROS can also activate a multiprotein complex called inflammasome, which regulates the activation of caspase-1 and subsequent maturation of pro-inflammatory cytokines (IL-1β and IL-18). The transcription factor Nrf2 plays a key role in the protection against oxidative stress in numerous inflammatory diseases since it regulates the transcription of antioxidant enzymes. Moreover, the participation of sirtuins, such as SIRT1 and SIRT6 and autophagy in this process is currently being studied.
In recent years, the need to find new anti-inflammatory molecules has raised the scientific community´s interest for marine natural products. In this regard, the marine environment represents an excellent source to isolate bioactive compounds from microbes, such as bacteria, cyanobacteria, fungi, algae or small invertebrates, such as sponges, tunicates, bryozoans and mollusks. This Special Issue of Marine Drugs will cover the entire scope of marine agents with anti-inflammatory activities, both in vitro and in vivo, as well as the latest status of clinical development from drug trials. In particular, works that evaluate molecular mechanisms of these compounds are especially encouraged.
Prof. Elena Talero
Dr. Javier Avila
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Marine compounds
- Antioxidant molecules
- Immune response
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Type of the Paper: Review
Title: Anti-inflammatory agents from marine sponges: an update
Authors: Nadia Ruocco 1,2,3, Luisa Albarano 1, Francesca Capone 4, Susan Costantini 4, Maria Costantini 1,*
1 Department of Biology and Evolution of Marine Organisms, Stazione Zoologica Anton Dohrn, Villa Comunale, 80121 Napoli, Italy
2 Department of Biology, University of Naples Federico II, Complesso Universitario di Monte Sant’Angelo, Via Cinthia, 80126, Napoli, Italy
3 Bio-Organic Chemistry Unit, Institute of Biomolecular Chemistry-CNR, Via Campi Flegrei 34, Pozzuoli, Naples 80078, Italy
4 Unità di Farmacologia Sperimentale, Istituto Nazionale Tumori “Fondazione G. Pascale”, IRCCS, Napoli, Italy
Correspondence: firstname.lastname@example.org; Tel.: +39-081-583-3315; Fax: +39-081-764-1355
Abstract: Inflammation is a dynamic process, in which proinflammatory cytokines (tumor necrosis factor, interleukin-1β and vascular endothelial growth factor) have central roles. A number of drugs or active agents have been developed to treat inflammation, able to reduce the activity of specific cytokines or their receptors (anticytokine therapies), block lymphocyte trafficking into tissues, prevent the binding of monocyte-lymphocyte costimulatory molecules, or deplete B lymphocytes. Furthermore, inflammation is a critical component of tumour progression, fostering new anti-inflammatory therapeutic approaches against cancer development. In the few last decades marine environment have been recognized to be a rich sources of bioactive metabolites with varied biological and pharmacological activities, including anti-inflammatory effects. A lot of marine phyla were considered for their significance respect to pharmacological active compounds, including bacteria, fungi, algae, soft corals, nudibranchs, bryozoans, tunicates and especially sponges. Marine sponges have been considered as a gold mine during the past few decades with respect to the diversity of their secondary metabolites and continue to provide novel natural products with a remarkable chemical diversity. Considering that the last review on anti-inflammatory agents from marine sponges dates back to 2005, and after this many studies report results on the identification of natural compounds from sponges with this activity, here we report an update on anti-inflammatory agents, focusing our attention on marine sponges as promising their sources.